1.58
0.00%
+0.00
Adaptimmune Therapeutics Plc ADR stock is currently priced at $1.58, with a 24-hour trading volume of 1.07M.
It has seen a +0.00% increased in the last 24 hours and a -1.86% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.56 pivot point. If it approaches the $1.65 resistance level, significant changes may occur.
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Financials Data
Adaptimmune Therapeutics Plc ADR (ADAP) Revenue 2023
ADAP reported a revenue (TTM) of $60.28 million for the quarter ending December 31, 2023, a +122.05% rise year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Net Income 2023
ADAP net income (TTM) was -$113.87 million for the quarter ending December 31, 2023, a +31.18% increase year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Cash Flow 2023
ADAP recorded a free cash flow (TTM) of -$145.76 million for the quarter ending December 31, 2023, a +15.01% increase year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings per Share 2023
ADAP earnings per share (TTM) was -$0.4738 for the quarter ending December 31, 2023, a +53.55% growth year-over-year.
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Latest News
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Benzinga
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
Zacks Investment Research
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Zacks Investment Research
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Zacks Investment Research
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
About Adaptimmune Therapeutics Plc ADR
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Cap:
|
Volume (24h):